Key result
Ticagrelor and prasugrel showed no significant difference in mortality (OR 1.00), major adverse cardiac events (OR 0.73), or bleeding events in patients with type 2 diabetes mellitus following percutaneous coronary intervention.
Why the study?
New generation P2Y12 inhibitors might potentially replace clopidogrel post-PCI for ACS, prompting a systematic comparison of post-interventional clinical outcomes and bleeding events with ticagrelor versus prasugrel in patients with T2DM.
Does ticagrelor improve clinical outcomes or reduce bleeding compared to prasugrel in patients with type 2 diabetes mellitus following percutaneous coronary intervention?
Population
2004 participants with T2DM following PCI
Comparison
Ticagrelor vs prasugrel
Design
Systematic review and meta-analysis
Authors
Loading...
Either agent may be used post-PCI in T2DM; confirms comparable ischemic and bleeding risks in this population.
Meta-Analysis (n=2,004)
Does ticagrelor improve clinical outcomes or reduce bleeding compared to prasugrel in patients with type 2 diabetes mellitus following percutaneous coronary intervention?
Odds Ratio: 1 (95% CI 0.57–1.76)
p-value: p=0.99
In patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention, ticagrelor and prasugrel have comparable efficacy and safety profiles with no significant differences in ischemic or bleeding outcomes.
Yang et al. (2018) conducted a meta-analysis in Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention (n=2,004). Ticagrelor vs. Prasugrel was evaluated on Mortality (OR 1.00, 95% CI 0.57-1.76, p=0.99). Ticagrelor and prasugrel showed no significant difference in mortality (OR 1.00), major adverse cardiac events (OR 0.73), or bleeding events in patients with type 2 diabetes mellitus following percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: